Darmiyan is a pioneering medical technology company specializing in brain health diagnostics. Their flagship product, BrainSee, is an FDA-approved, AI-powered software platform designed to predict the progression from amnestic mild cognitive impairment (aMCI) to Alzheimer's dementia within a five-year timeframe. By integrating standard clinical MRI scans with cognitive assessments, BrainSee generates an objective score that assists physicians in evaluating a patient's risk of developing Alzheimer's disease. Key Features and Functionality: - Advanced Image Analysis: Utilizes proprietary algorithms to analyze whole-brain MRI scans, detecting subtle cellular-level changes indicative of neurodegeneration. - AI Integration: Employs artificial intelligence to enhance diagnostic accuracy and provide predictive insights. - Non-Invasive Testing: Offers a non-invasive method for assessing brain health, eliminating the need for more invasive procedures. - Rapid Results: Delivers same-day test results, facilitating timely clinical decision-making. - Clinical Workflow Integration: Designed to seamlessly integrate into existing clinical workflows, enhancing efficiency for healthcare providers. Primary Value and User Benefits: BrainSee addresses the critical need for early detection and risk stratification in Alzheimer's disease. By identifying individuals at higher risk of progression from aMCI to Alzheimer's dementia, it enables proactive management strategies, potentially delaying the onset of dementia symptoms. For patients at lower risk, BrainSee provides reassurance, reducing the necessity for costly and invasive tests. This approach transforms the patient experience from prolonged uncertainty to proactive health management, ultimately aiming to improve quality of life and reduce the emotional and financial burdens associated with Alzheimer's disease.